Cargando…

Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer

Custirsen is the second-generation antisense oligonucleotide (ASO), which can reduce cellular levels of clusterin to increase the cytotoxic effect of chemotherapeutic drugs. Our study assessed the efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer (mCRP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xuebao, Liu, Chu, Li, Kui, Wang, Ke, Zhang, Qiqiang, Cui, Yuanshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380863/ https://www.ncbi.nlm.nih.gov/pubmed/30732140 http://dx.doi.org/10.1097/MD.0000000000014254

Ejemplares similares

Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen
por: Blumenstein, Brent, et al.
Publicado: (2013)

Potential use of custirsen to treat prostate cancer
por: Higano, Celestia S
Publicado: (2013)

Total laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma under a single surgical position
por: Zhang, Xuebao, et al.
Publicado: (2019)

Meta-analysis of the efficacy of sexual intercourse for distal ureteric stones
por: Xu, Bin, et al.
Publicado: (2019)

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wei, ZhenHeng, et al.
Publicado: (2021)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
por: Wang, Xing-Hui, et al.
Publicado: (2022)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer: A meta-analysis of randomized controlled trials
por: Gong, Ping, et al.
Publicado: (2018)

Pooled analysis of efficacy and safety of ureteral stent removal using an extraction string
por: Sun, Xujie, et al.
Publicado: (2019)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Efficacy and Safety of (225)Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Ma, Jiao, et al.
Publicado: (2022)

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wu, Kan, et al.
Publicado: (2021)

Meta-Analysis of the Long-Term Efficacy and Tolerance of Tadalafil Daily Compared With Tadalafil On-Demand in Treating Men With Erectile Dysfunction
por: Zhou, Zhongbao, et al.
Publicado: (2019)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
por: Yamamoto, Teppei, et al.
Publicado: (2020)

Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials
por: Luo, Zhanyang, et al.
Publicado: (2023)

A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer
por: Alameddine, Zakaria, et al.
Publicado: (2023)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
por: Yadav, Madhav Prasad, et al.
Publicado: (2020)

A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer
por: Samar, Aseem, et al.
Publicado: (2020)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer
por: Pang, Xiaocong, et al.
Publicado: (2019)

The Efficacy and Safety of Holmium Laser Enucleation of Prostate Compared With Bipolar Technologies in Treating Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials
por: Che, Xuanyan, et al.
Publicado: (2022)

Phosphodiesterase-5 Inhibitors for Premature Ejaculation: Systematic Review and Meta-Analysis of Placebo-Controlled Trials
por: Zhang, Xuebao, et al.
Publicado: (2020)

Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy
por: Cai, Tong, et al.
Publicado: (2020)

Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials
por: Zhou, Zhongbao, et al.
Publicado: (2020)

Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
por: Zhang, Jingsong, et al.
Publicado: (2017)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
por: Pollard, Matthew E., et al.
Publicado: (2017)

Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mjfh73n12m4n9m7vj1g9d8eumi